{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:31:42Z","timestamp":1784064702107,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Dolutegravir (DTG) was scaled up globally to optimize treatment for children living with HIV. We evaluated the rollout and virological outcomes after DTG introduction in Mozambique.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data from children 0\u201314 years with visits from September 2019 to August 2021 were extracted from records in 16 facilities in 12 districts. Among children ever on DTG, we report treatment switches, defined as changes in anchor drug, regardless of changes to nucleoside reverse transcriptase inhibitor (NRTI) backbones. Among those on DTG for \u22656 months, we described viral load suppression rates by children newly initiating and switching to DTG and by the NRTI backbone at the time of the DTG switch.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, 3,347 children were ever on DTG-based treatment (median age 9.5 years; 52.8% female). Most children (3,202, 95.7%) switched to DTG from another antiretroviral regimen. During the 2-year follow-up, 9.9% never switched from DTG; 52.7% had 1 regimen change, of which 97.6% were switched to DTG. However, 37.2% of children experienced \u22652 anchor drug changes. Overall median time on DTG was 18.6 months; nearly all children \u22655 years (98.6%) were on DTG at the last visit. Viral suppression was 79.7% (63\/79) for children newly initiating DTG and 85.8% (1,775\/2,068) for those switching to DTG. Suppression rates were 84.8% and 85.7% among children who switched and maintained NRTI backbones, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Viral suppression rates of \u226580% with minor variations by backbone were achieved during the 2-year DTG rollout. However, there were multiple anchor drug switches for over one-third of children, which may be attributable in part to drug stockouts. Long-term pediatric HIV management will only be successful with immediate and sustainable access to optimized child-friendly drugs and formulations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004037","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T13:00:31Z","timestamp":1688648431000},"page":"893-898","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Virologic Outcomes and ARV Switch Profiles 2 Years After National Rollout of Dolutegravir to Children Less Than 15 Years in Southern Mozambique"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7391-6947","authenticated-orcid":false,"given":"Michelle M.","family":"Gill","sequence":"first","affiliation":[{"name":"Research Department, Elizabeth Glaser Pediatric AIDS Foundation, Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Herrera","sequence":"additional","affiliation":[{"name":"Research Department, Elizabeth Glaser Pediatric AIDS Foundation, Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guilaze","sequence":"additional","affiliation":[{"name":"Research Department, Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Mussa","sequence":"additional","affiliation":[{"name":"Research Department, Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataniel","family":"Dengo","sequence":"additional","affiliation":[{"name":"Research Department, Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amancio","family":"Nhangave","sequence":"additional","affiliation":[{"name":"Gaza Provincial Health Directorate, Mozambique Ministry of Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaciara","family":"Muss\u00e1","sequence":"additional","affiliation":[{"name":"Inhambane Provincial Health Directorate, Mozambique Ministry of Health."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Perez","sequence":"additional","affiliation":[{"name":"Research Department, Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Research Department, Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1016\/S2352-3018(19)30193-6","article-title":"Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.","volume":"6","author":"Penazzato","year":"2019","journal-title":"Lancet HIV"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1186\/s12879-021-06459-z","article-title":"HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.","volume":"21","author":"Afrane","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/jpids\/piaa030","article-title":"Prevalence and factors associated with virological treatment failure among children and adolescents on antiretroviral therapy attending HIV\/AIDS care and treatment clinics in Dodoma Municipality, Central Tanzania.","volume":"10","author":"Bitwale","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/cid\/cix698","article-title":"Human immunodeficiency virus (HIV) drug resistance in African infants and young children newly diagnosed with HIV: A multicountry analysis.","volume":"65","author":"Jordan","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0000000000001553","article-title":"High prevalence of HIV drug resistance among newly diagnosed infants aged <18 months: Results from a nationwide surveillance in Nigeria.","volume":"77","author":"Inzaule","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV.","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first- or second-line treatment for HIV-1 infection in children.","volume":"385","author":"Turkova","year":"2021","journal-title":"N Engl J Med"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"e25970","DOI":"10.1002\/jia2.25970","article-title":"Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.","volume":"25","author":"Townsend","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/QAD.0000000000003154","article-title":"Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya.","volume":"36","author":"Kingwara","year":"2022","journal-title":"AIDS"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/hiv.13298","article-title":"Antiretroviral drug switches to zidovudine-based regimens and loss to follow-up during the first COVID-19 lockdown in Bali, Indonesia.","volume":"23","author":"Gedela","year":"2022","journal-title":"HIV Med"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1186\/s12889-022-13504-2","article-title":"Viral load monitoring for people living with HIV in the era of test and treat: progress made and challenges ahead \u2013 a systematic review.","volume":"22","author":"Pham","year":"2022","journal-title":"BMC Public Health"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"e26036","DOI":"10.1002\/jia2.26036","article-title":"Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium.","volume":"25","author":"Brazier","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"e26033","DOI":"10.1002\/jia2.26033","article-title":"Protecting the gains: analysis of HIV treatment and service delivery programme data and interventions implemented in 19 African countries during COVID-19.","volume":"25","author":"Bachanas","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"23259582221109613","DOI":"10.1177\/23259582221109613","article-title":"Adherence, effectiveness and safety of Dolutegravir based antiretroviral regimens among HIV infected children and adolescents in Tanzania.","volume":"21","author":"Mutagonda","year":"2022","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jpids\/piy139","article-title":"Long-term safety and efficacy of Dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the IMPAACT P1093 Study.","volume":"9","author":"Viani","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/hiv.13154","article-title":"Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.","volume":"22","author":"Frange","year":"2021","journal-title":"HIV Med"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"e0261611","DOI":"10.1371\/journal.pone.0261611","article-title":"Prevalence and associated factors of treatment failure among children on ART in Ethiopia: a systematic review and meta-analysis.","volume":"17","author":"Gelaw","year":"2022","journal-title":"PLoS One"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/QAD.0000000000002470","article-title":"Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.","volume":"34","author":"Salou","year":"2020","journal-title":"AIDS"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance.","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:05:34Z","timestamp":1749945934000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004037","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}